1. Home
  2. WST vs INSM Comparison

WST vs INSM Comparison

Compare WST & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo West Pharmaceutical Services Inc.

WST

West Pharmaceutical Services Inc.

HOLD

Current Price

$346.61

Market Cap

25.6B

Sector

Health Care

ML Signal

HOLD

Logo Insmed Incorporated

INSM

Insmed Incorporated

HOLD

Current Price

$128.32

Market Cap

22.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WST
INSM
Founded
1923
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.6B
22.4B
IPO Year
2004
2000

Fundamental Metrics

Financial Performance
Metric
WST
INSM
Price
$346.61
$128.32
Analyst Decision
Buy
Strong Buy
Analyst Count
7
24
Target Price
$325.86
$201.17
AVG Volume (30 Days)
640.3K
3.1M
Earning Date
04-23-2026
05-07-2026
Dividend Yield
0.30%
N/A
EPS Growth
1.49
N/A
EPS
4.07
N/A
Revenue
$2,886,900,000.00
N/A
Revenue This Year
$6.76
$182.31
Revenue Next Year
$6.22
$65.19
P/E Ratio
$85.87
N/A
Revenue Growth
1.95
N/A
52 Week Low
$223.83
$90.39
52 Week High
$386.00
$212.75

Technical Indicators

Market Signals
Indicator
WST
INSM
Relative Strength Index (RSI) 52.99 62.28
Support Level $349.41 $95.24
Resistance Level $358.67 $140.30
Average True Range (ATR) 6.59 4.89
MACD -0.03 1.80
Stochastic Oscillator 70.98 74.10

Price Performance

Historical Comparison
WST
INSM

About WST West Pharmaceutical Services Inc.

West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

Share on Social Networks: